Chardan Healthcare Acquisition 2 Corp. (CHAQ): Price and Financial Metrics
CHAQ Price/Volume Stats
| Current price | $8.41 | 52-week high | $11.12 |
| Prev. close | $9.36 | 52-week low | $8.06 |
| Day low | $8.06 | Volume | 242,600 |
| Day high | $9.35 | Avg. volume | 55,653 |
| 50-day MA | $9.95 | Dividend yield | N/A |
| 200-day MA | $10.10 | Market Cap | 90.64M |
CHAQ Stock Price Chart Interactive Chart >
Chardan Healthcare Acquisition 2 Corp. (CHAQ) Company Bio
Chardan Healthcare Acquisition 2 Corp. intends to acquire assets and businesses through a merger, share exchange, stock purchase, recapitalization, reorganization, or other similar business combination. The company was founded in 2018 and is based in New York, New York.
Latest CHAQ News From Around the Web
Below are the latest news stories about Chardan Healthcare Acquisition 2 Corp that investors may wish to consider to help them evaluate CHAQ as an investment opportunity.
Chardan Healthcare Acquisition 2 Corp. Announces Stockholder Approval Of Business Combination With Renovacor, Inc.Chardan Healthcare Acquisition 2 Corp. (NYSE: CHAQ) ("CHAQ"), a special purpose acquisition company sponsored by Chardan Capital Markets ("Chardan"), today announced the results for the proposals considered and voted upon by its stockholders at its special meeting held on September 1, 2021 (the "Special Meeting"), regarding the proposed business combination with Renovacor, Inc. ("Renovacor"), an early‑stage biotechnology company developing adeno-associated virus (AAV)‑based gene therapies for de |
Chardan Healthcare Acquisition 2 Corp. Announces Renovacor's Appointment of Matt Killeen, Ph.D., as Chief Scientific OfficerRenovacor, Inc. ("Renovacor"), an early–stage biotechnology company developing adeno-associated virus (AAV)–based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene variants, today announced the appointment of Matt Killeen, Ph.D., as chief scientific officer (CSO), effective as of September 1, 2021. Chardan Healthcare Acquisition 2 Corp. (CHAQ) previously announced on March 23, 2021 that it entered into a definitive merger agreement with Re |
Chardan Healthcare Acquisition 2 Corp. Announces Record Date for Stockholders Eligible to Vote on MergerPHILADELPHIA and NEW YORK, Aug. 3, 2021 /PRNewswire/ -- Chardan Healthcare Acquisition 2 Corp. (the "Company") announced that the close of business on Thursday, August 5, 2021, has been set as the record date for the determination of stockholders eligible to receive the proxy and vote at |
Renovacor Announces the Appointment of Elizabeth White, Ph.D., as Chief Business Officer and Senior Vice President of OperationsDr. White is an industry leader with over three decades of pharmaceutical experience in business management and strategy with a focus on rare diseases and gene therapiesPHILADELPHIA, July 19, 2021 (GLOBE NEWSWIRE) -- Renovacor, Inc. (“Renovacor”), an early‑stage biotechnology company developing adeno-associated virus (AAV)‑based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene variants, today announced the appointment of Elizabeth (Beth) |
Renovacor Announces the Appointment of Jiwen Zhang, Ph.D., as Senior Vice President, Regulatory Affairs and Quality AssuranceDr. Zhang has over 20 years of experience in regulatory affairs, with over a decade specifically in the field of cell and gene therapyPHILADELPHIA, July 12, 2021 (GLOBE NEWSWIRE) -- Renovacor, Inc. (“Renovacor”), an early‑stage biotechnology company developing adeno-associated virus (AAV)‑based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene variants, today announced the appointment of Jiwen Zhang, Ph.D., as senior vice president, regula |
CHAQ Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | -15.31% |
| 5-year | N/A |
| YTD | N/A |
| 2022 | N/A |
| 2021 | 0.00% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...